Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

References

• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–172.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330–1340.
   PubMed Web of Science ®Google Scholar
• Radich JP, Dai H, Mao M, et al Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794–2799.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, et al Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513–521.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Berger U, Pfirrmann M, et al Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686–4692.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615–619.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams G, Johnson JR, et al Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935–942.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Imatinib prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
   Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, et al Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, et al Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, et al Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928–1937.
   PubMed Web of Science ®Google Scholar
• Lee FY, Lombardo L, Camuso A, et al BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005;46: Abstract 675.
   Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al Discovery of N-(2-chloro-6-methyl-phenyl)- 2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)- 2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–6661.
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, et al Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185–9189.
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, et al Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473–481.
   PubMed Web of Science ®Google Scholar
• Shah NP, Lee FY, Luo R, et al Dasatinib (BMS-354825) inhibits KITD816V, an imatinib resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286–291.
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Mayerhofer M, Sonneck K, et al Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816Vmutated oncogenic variant of KIT. Hematologica 2007;92:1451–1459.
   PubMed Web of Science ®Google Scholar
• Kneidinger M, Schmidt U, Rix U, et al The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils. Blood 2008;111:3097–3107.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Dasatinib prescribing information. Princeton, NJ: Bristol-Myers Squibb Co.; 2009.
   Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, et al In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Nilotinib prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
   Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, et al Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345–356.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913–923.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374–7379.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, et al Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190–2196.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117–125.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374–7379.
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–2653.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345–356.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Corm S, Le QH, et al Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP). Leukemia 2006;20:1061–1066.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–1773.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Benichou A, Khoury HJ, Corm S, et al Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation. J Clin Oncol 2008;26:377s (Abstract 7021).
   Google Scholar
• Copland M, Pellicano F, Richmond L, et al BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111:2843–2853.
   PubMed Web of Science ®Google Scholar
• Cortes J, Quintas-Cardama A, Garcia-Manero G, et al Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007;110:2000–2006.
   PubMed Web of Science ®Google Scholar
• Paquette RL, Shah NP, Sawyers CL, et al PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 2007;110:312a (Abstract 1030).
   Web of Science ®Google Scholar
• Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996;56:3589–3596.
   PubMed Web of Science ®Google Scholar
• Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997;272:33260–33270.
   PubMed Web of Science ®Google Scholar
• Benati D, Baldari CT. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem 2008;15:1154–1165.
   PubMed Web of Science ®Google Scholar
• Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000;275:18581–18585.
   PubMed Web of Science ®Google Scholar
• Meyn MA, III, Wilson MB, Abdi FA, et al Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006;281:30907–30916.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690–698.
   PubMed Web of Science ®Google Scholar
• Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006;103:16870–16875.
   PubMed Web of Science ®Google Scholar
• Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004;10:1187–1189.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672–677.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu J, Kong LY, Meng F, Lee FY, Talpaz M. Constitutive activation of SRC-family kinases in chronic myelogenous leukemia patients resistant to imatinib mesylate in the absence of BCR-ABL mutations: a rationale for use of SRC/ABL dual kinase inhibitor-based therapy. Blood 2005;106:316A (Abstract 1087).
   Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, et al Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236–4243.
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938–1942.
   PubMed Web of Science ®Google Scholar
• Holyoake TL, Jiang X, Drummond MW, et al Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 2002;16:549–558.
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, et al Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701–4707.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Smith C, et al Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926–935.
   PubMed Web of Science ®Google Scholar
• Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 2008;142:361–378.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Forrest D, et al Stem cell biomarkers in chronic myeloid leukemia. Dis Markers 2008;2494–2450:201–216.
   Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
   PubMed Web of Science ®Google Scholar
• Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia 2005;19:1590–1596.
   PubMed Web of Science ®Google Scholar
• Burchert A, Wang Y, Cai D, et al Compensatory PI3-kinase//Akt//mTor activation regulates imatinib resistance development. Leukemia 2005;19:1774–1782.
   PubMed Web of Science ®Google Scholar
• Bumm T, Muller C, Al-Ali HK, et al Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941–1949.
   PubMed Web of Science ®Google Scholar
• Athanasiadou A, Stavroyianni N, Saloum R, Asteriou O, Anagnostopoulos A, Fassas A. Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases. Leukemia 2004;18:1029–1031.
   PubMed Web of Science ®Google Scholar
• Deininger MW. Cytogenetic studies in patients on imatinib. Semin Hematol 2003;40(Suppl 2):50–55.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Gozzetti A, Galimberti S, et al Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 2007;109:2466–2472.
   PubMed Web of Science ®Google Scholar
• Perel JM, McCarthy C, Walker O, Irving I, Williams B, Kennedy GA. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2005;90(Suppl):ECR25.
   PubMedGoogle Scholar
• Bradeen HA, Eide CA, O'Hare T, et al Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332–2338.
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108:1328–1333.
   PubMed Web of Science ®Google Scholar
• Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109:5011–5015.
   PubMed Web of Science ®Google Scholar
• Gambacorti C, Cortes J, Kim DW, et al Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood 2007;110:145a (Abstract 472).
   Web of Science ®Google Scholar
• Guilhot F, Apperley JF, Kim DW, et al Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 2007;110:145a (Abstract 470).
   Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Cortes J, et al Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood 2007;110:226a (Abstract 735).
   Web of Science ®Google Scholar
• le Coutre P, Giles F, Apperley J, et al Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. Blood 2007;110:145a (Abstract 471).
   Web of Science ®Google Scholar
• Porkka K, Simonsson B, Dombret H, et al Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015). Blood 2007;110:826a (Abstract 2810).
   Web of Science ®Google Scholar
• Stone RM, Kantarjian HM, Baccarani M, et al Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). Blood 2007;110:225a (Abstract 734).
   Web of Science ®Google Scholar
• Giles FJ, Larson RA, Kantarjian HM, et al Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 2007;110:310a (Abstract 1025).
   Web of Science ®Google Scholar
• Ottmann OG, Larson RA, Kantarjian HM, et al Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) who are resistant or intolerant to imatinib. Blood 2007;110:828a (Abstract 2815).
   Web of Science ®Google Scholar
• Mueller MC, Branford S, Radich J, et al Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. Haematologica 2007;92(Suppl 2):127 (Abstract 0356).
   PubMed Web of Science ®Google Scholar
• Mueller MC, Erben P, Ernst T, et al Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapy in chronic phase CML patients. Blood 2007;110:100a (Abstract 319).
   Web of Science ®Google Scholar
• Hughes T, Saglio G, Martinelli G, et al Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. Blood 2007;110:101a (Abstract 320).
   Web of Science ®Google Scholar
• Saglio G, Kim DW, Hochhaus A, et al Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance. Blood 2007;110:576a (Abstract 1940).
   Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401–404.
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs BJ, Branford S, et al Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562–2569.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Milojkovic D, Mehta P, et al In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008;111:2378–2381.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™: chronic myelogenous leukemia, V.1.2008 [Internet]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf. [Accessed September 2008].
   Google Scholar
• Donato NJ, Wu J, Kong LY, Meng F, Lee FY, Talpaz M. Constitutive activation of SRC-family kinases in chronic myelogenous leukemia patients resistant to imatinib mesylate in the absence of BCR-ABL mutations: a rationale for use of SRC/ABL dual kinase inhibitor-based therapy. Blood 2005;106:316A (Abstract 1087).
   Web of Science ®Google Scholar
• Hiwase DK, White DL, Saunders VA, et al In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. Blood 2007;110:575a–576a (Abstract 1937).
   Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.
   PubMed Web of Science ®Google Scholar
• Davies A, Giannoudis A, Lucas CM, et al Characterisation of nilotinib transport in chronic myeloid leukaemia cells. Blood 2007;110:698a (Abstract 2364).
   Web of Science ®Google Scholar
• Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008;61:365–376.
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, et al Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532–4539.
   PubMed Web of Science ®Google Scholar
• Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells. Blood 2007;109:4016–4019.
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, et al Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267–1275.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Schiffer C, Sawyers CL, et al Imatinib (Gleevec) maintains favorable long-term outcomes in chronic-phase chronic myeloid leukemia (CML) for patients failing interferon-α (IFN) follow-up of a phase II study. Blood 2003;102:905a (Abstract 3368).
   Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, O'Brien S, et al Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res 2002;8:2177–2187.
   PubMed Web of Science ®Google Scholar
• Marin D, Marktel S, Bua M, et al Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon-α. Leukemia 2003;17:1448–1453.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Goldman J, Sawyers C, et al High dose imatinib (STI571, Gleevec) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC): follow-up of the phase II studies. Blood 2003;102:905a (Abstract 3369).
   Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, et al Frequency of major molecular responses to imatinib or interferon-α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian HM, O'Brien SM, et al Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). J Clin Oncol 2008;26:375s (Abstract 7013).
   Google Scholar
• Cortes J, O'Brien S, Jones D, et al Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 2008;112:170 (Abstract 446).
   Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M, et al Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200–1206.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Baccarani M, Cervantes F, et al Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26:374s (Abstract 7009).
   PubMed Web of Science ®Google Scholar
• Rea D, Dombret H, Kim DW, et al Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A. Haematologica 2008;93(Suppl 1):391 (Abstract 0982).
   Google Scholar
• Saglio G, Dombret H, Rea D, et al Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. Haematologica 2008;93(Suppl 1):349 (Abstract 0880).
   Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Hochhaus A, et al Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results. J Clin Oncol 2008;26:374s (Abstract 7010).
   PubMed Web of Science ®Google Scholar
• le Coutre P, Giles FJ, Apperley J, et al Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or –intolerance: update of a phase II study. J Clin Oncol 2008;26:384s (Abstract 7050).
   Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–3546.
   PubMed Web of Science ®Google Scholar
• Singer JB, Shou Y, Giles F, et al UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21:2311–2315.
   PubMed Web of Science ®Google Scholar
• Golas JM, Arndt K, Etienne C, et al SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375–381.
   PubMed Web of Science ®Google Scholar
• Kimura S, Naito H, Segawa H, et al NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106:3948–3954.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian HM, Baccarani M, et al A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 2006;108 (Abstract 168).
   Web of Science ®Google Scholar
• Yokota A, Kimura S, Masuda S, et al INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306–314.
   PubMed Web of Science ®Google Scholar
• Carter TA, Wodicka LM, Shah NP, et al Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011–11016.
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, et al VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262–267.
   PubMed Web of Science ®Google Scholar
• Young MA, Shah NP, Chao LH, et al Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007–1014.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500–502.
   PubMed Web of Science ®Google Scholar
• Zhang W. Inhibition of the drug-resistant T315I mutant of BCR-Abl. Eur J Cancer 2006;Suppl 4[12]:54 (Abstract 171).
   Web of Science ®Google Scholar
• Shakespeare WC, Wang F, Xu Q, et al Orally active inhibitors of the imatinib resistant Bcr-Abl mutant T315I. Blood 2006;108:618A (Abstract 2150).
   PubMed Web of Science ®Google Scholar
• Bartholomeusz GA, Talpaz M, Kapuria V, et al Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007;109:3470–3478.
   PubMed Web of Science ®Google Scholar
• Legros L, Hayette S, Nicolini FE, et al BCR-ABL (T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 2007;21:2204–2206.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248–255.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, et al Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005;11:6987–6993.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Catley L, Wright RD, et al Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109:2112–2120.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Pranpat M, Bali P, et al Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006;108:645–652.
   PubMed Web of Science ®Google Scholar